How Gilead’s Liver Disease Drugs Portfolio Performed
Gilead’s liver disease drugs
As discussed earlier, Gilead’s (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver disease, oncology, cardiovascular, inflammation, respiratory, and others. Over 50% of revenues comes from antiviral products from the liver disease franchise.
Interested in GILD? Don't miss the next report.
Receive e-mail alerts for new research on GILD
Liver disease drugs portfolio
The liver disease drugs portfolio includes drugs like Sovaldi, Viread, Harvoni, Hepsera, and Epclusa.
Harvoni is Gilead’s best-selling drug. Harvoni is used with or without ribavirin for the treatment of chronic hepatitis C virus of genotype-1, genotype-4, genotype-5, and genotype-6. Harvoni reported a decline in revenues of $9.1 billion for 2016 as compared to $13.9 billion for 2015.
Sovaldi is a drug used in combination with other antivirals for the treatment of chronic hepatitis C virus of genotype-1 to genotype-4. Sovaldi reported revenues of $4.0 billion in 2016 as compared to $5.3 billion for 2015.
Viread is used in combination with other antiretrovirals for the treatment of patients with HIV-1 infection. It’s also used for the treatment of patients with Hepatitis B virus infection. However, the drug Viread should not be used in combination with other drugs like Atripla, Complera, Stribild, and Truvada. Viread reported revenues of $1.2 billion for 2016 as compared to $1.8 billion for 2015.
Epclusa is a new drug for the treatment of chronic Hepatitis C infection of Genotype-1 to Genotype-6 with or without cirrhosis. For patients who have advanced cirrhosis, the drug is used in combination with Ribavirin. Epclusa will be a new blockbuster drug for the treatment of patients with Hepatitis C infections. The drug reported revenues of $1.8 billion for 2016.
Some of the approved treatments for HCV include Zepatier from Merck (MRK), Daklinza from Bristol-Myers Squibb (BMY), Technivie and Viekira Pak from AbbVie (ABBV), and Olysio for Johnson & Johnson (JNJ).
To divest the risk, investors can consider ETFs like the SPDR S&P Biotech ETF (XBI), which holds ~2.2% of its total assets in Gilead Sciences.